Oppenheimer Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $18
Evolent Health Is Maintained at Outperform by Oppenheimer
JMP Securities Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $12
Evolent Health (EVH) Receives a Buy From JMP Securities
CCORF Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $16
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $15
BTIG Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $20
Stephens Initiates Evolent Health(EVH.US) With Hold Rating, Announces Target Price $12
Evolent Health Is Maintained at Buy by UBS
Evolent Health Analyst Ratings
UBS Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $14
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $20
Needham Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $15
Evolent Health's Strategic Moves and Financial Outlook Garner Buy Rating From Analyst Matthew Shea
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $17
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Announces Target Price $20
Evolent Health Is Maintained at Market Outperform by JMP Securities
Citi Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $18
Evolent Health Analyst Ratings
Evolent Health's Strategic Positioning and Future Growth: Buy Rating Amidst Financial Adjustments and Market Opportunities